<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Jpn Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">Jpn Clin Med</journal-id><journal-id journal-id-type="publisher-id">Japanese Clinical Medicine</journal-id><journal-title-group><journal-title>Japanese Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">1179-6707</issn><publisher><publisher-name>Libertas Academica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26568687</article-id><article-id pub-id-type="pmc">4631162</article-id><article-id pub-id-type="doi">10.4137/JCM.S32018</article-id><article-id pub-id-type="publisher-id">jcm-6-2015-029</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Serum Biopterin and Neopterin Levels as Predictors of Empty Follicles</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hamuro</surname><given-names>Akihiro</given-names></name><xref ref-type="aff" rid="af1-jcm-6-2015-029">1</xref><xref ref-type="corresp" rid="c1-jcm-6-2015-029"/></contrib><contrib contrib-type="author"><name><surname>Tachibana</surname><given-names>Daisuke</given-names></name><xref ref-type="aff" rid="af1-jcm-6-2015-029">1</xref></contrib><contrib contrib-type="author"><name><surname>Misugi</surname><given-names>Takuya</given-names></name><xref ref-type="aff" rid="af1-jcm-6-2015-029">1</xref></contrib><contrib contrib-type="author"><name><surname>Katayama</surname><given-names>Hiroko</given-names></name><xref ref-type="aff" rid="af1-jcm-6-2015-029">1</xref></contrib><contrib contrib-type="author"><name><surname>Ozaki</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="af1-jcm-6-2015-029">1</xref></contrib><contrib contrib-type="author"><name><surname>Fujino</surname><given-names>Yuji</given-names></name><xref ref-type="aff" rid="af2-jcm-6-2015-029">2</xref></contrib><contrib contrib-type="author"><name><surname>Yoshihiro</surname><given-names>Nakamura</given-names></name><xref ref-type="aff" rid="af3-jcm-6-2015-029">3</xref></contrib><contrib contrib-type="author"><name><surname>Shintaku</surname><given-names>Haruo</given-names></name><xref ref-type="aff" rid="af4-jcm-6-2015-029">4</xref></contrib><contrib contrib-type="author"><name><surname>Koyama</surname><given-names>Masayasu</given-names></name><xref ref-type="aff" rid="af1-jcm-6-2015-029">1</xref></contrib></contrib-group><aff id="af1-jcm-6-2015-029"><label>1</label>Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka, Japan.</aff><aff id="af2-jcm-6-2015-029"><label>2</label>Fujino Ladies Clinic, Osaka, Japan.</aff><aff id="af3-jcm-6-2015-029"><label>3</label>Nakamura Ladies Clinic, Osaka, Japan.</aff><aff id="af4-jcm-6-2015-029"><label>4</label>Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan.</aff><author-notes><corresp id="c1-jcm-6-2015-029">CORRESPONDENCE: <email>hamuroa@med.osaka-cu.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>02</day><month>11</month><year>2015</year></pub-date><volume>6</volume><fpage>29</fpage><lpage>34</lpage><history><date date-type="received"><day>22</day><month>7</month><year>2015</year></date><date date-type="rev-recd"><day>30</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>07</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 the author(s), publisher and licensee Libertas Academica Ltd.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.</license-p></license></permissions><abstract><sec><title>OBJECTIVE</title><p>This study measured serum and follicular fluid (FF) levels of biopterin, neopterin, vascular endothelial growth factor (VEGF), and macrophage colony-stimulating factor (M-CSF) in patients receiving mild ovarian stimulation for oocyte retrieval.</p></sec><sec><title>PATIENTS AND METHODS</title><p>Infertile patients who underwent ovarian stimulation were divided into the following: Group 1, no oocyte retrieval (<italic>n</italic> = 12), and Group 2, retrieval of more than four oocytes (<italic>n</italic> = 13). Median total gonadotropin dose in both groups was 150 IU. Biopterin and neopterin levels were measured using high-performance liquid chromatography. VEGF and M-CSF levels were measured by enzyme-linked immunosorbent assay.</p></sec><sec><title>RESULTS</title><p>Compared to Group 2, serum and FF levels of neopterin and VEGF and serum levels of M-CSF were significantly increased, and serum and FF levels of biopterin were significantly decreased in Group 1 (<italic>P</italic> &#x0003c; 0.05 each).</p></sec><sec><title>CONCLUSION</title><p>Biopterin and neopterin levels showed similar differences in FF and serum of patients with empty follicles. Decreased biopterin and increased neopterin in serum could predict poor oocyte retrieval.</p></sec></abstract><kwd-group><kwd>biopterin</kwd><kwd>neopterin</kwd><kwd>VEGF</kwd><kwd>M-CSF</kwd><kwd>ovarian folliculogenesis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Ovarian folliculogenesis has been shown to be supported by nitric oxide (NO) production and vascular endothelial growth factor (VEGF).<xref rid="b1-jcm-6-2015-029" ref-type="bibr">1</xref> NO is synthesized from <sc>l</sc>-arginine by NO synthase (NOS) and plays a pivotal role in follicular angiogenesis.<xref rid="b2-jcm-6-2015-029" ref-type="bibr">2</xref> This process is thought to be initiated by VEGF signaling.<xref rid="b3-jcm-6-2015-029" ref-type="bibr">3</xref> Elevated VEGF levels in follicular fluid (FF) at the time of oocyte retrieval are reportedly associated with poor conception rates after in vitro fertilization (IVF) and gamete intrafallopian transfer.<xref rid="b4-jcm-6-2015-029" ref-type="bibr">4</xref> Similarly, levels of VEGF and NO in FF have been shown to correlate negatively with embryo quality as judged by morphology scoring from in vitro culture.<xref rid="b5-jcm-6-2015-029" ref-type="bibr">5</xref></p><p>NOS activity depends on the availability of cofactors such as tetrahydrobiopterin (BH<sub>4</sub>).<xref rid="b6-jcm-6-2015-029" ref-type="bibr">6</xref> Biosynthesis of BH<sub>4</sub> starts from guanosine triphosphate (GTP), which is converted to 7,8-dihydroneopterin and then further converted to BH<sub>4</sub> in the presence of 6-pyruvoyl tetrahydropterin synthase (PTPS). BH<sub>4</sub> also serves as an essential cofactor for the hydroxylation of aromatic amino acids. In this process, BH<sub>4</sub> is converted to dihydrobiopterin (BH<sub>2</sub>). Furthermore, BH<sub>2</sub> is reduced to BH<sub>4</sub> by dihydropteridine reductase. BH<sub>4</sub> and BH<sub>2</sub> are oxidized to biopterin and 7,8-dihydroneopterin is oxidized to neopterin, and these forms are detectable due to their fluorescence,<xref rid="b7-jcm-6-2015-029" ref-type="bibr">7</xref>,<xref rid="b8-jcm-6-2015-029" ref-type="bibr">8</xref> although their roles in FF have not yet been investigated.</p><p>The aim of this study was to assess the concentrations of biopterin, neopterin, VEGF, and macrophage colony-stimulating factor (M-CSF) in the serum and FF of women attempting to become pregnant with IVF using the low-gonadotropin (mild stimulation) method.</p></sec><sec sec-type="methods"><title>Material and Methods</title><p>Between May and September 2013, a total of 147 infertile patients were treated with mild ovarian stimulation at Fujino Ladies Clinic, which has since changed its name to Nakamura Ladies Clinic.<xref rid="b9-jcm-6-2015-029" ref-type="bibr">9</xref>,<xref rid="b10-jcm-6-2015-029" ref-type="bibr">10</xref> Indications for IVF included tubal occlusion (<italic>n</italic> = 3), endometriosis (<italic>n</italic> = 2), male factor (<italic>n</italic> = 2), and unexplained infertility (<italic>n</italic> = 18). Of these patients, those with an empty follicle were allocated to Group 1 (<italic>n</italic> = 13), while those from whom more than four oocytes (4&#x02013;12 oocytes) were retrieved were allocated to Group 2 (<italic>n</italic> = 12).</p><p>For each individual from whom FF samples were available, only FF from a single cycle was analyzed. Records of all IVF procedures were reviewed to collect the following data: age, body mass index, duration of infertility, serum estradiol (E2) and luteinizing hormone (LH) (48 hours before oocyte retrieval), and total dose of gonadotropin. We punctured the follicle using a single-puncture method. Induction of ovulation was monitored by transvaginal sonography with a 5-MHz transvaginal probe. The dose of gonadotropin for stimulation was then adjusted according to serum E2 concentrations and the size of ovarian follicles as evaluated by ultrasonography. Clomifene citrate was administered on day 5 after the start of menstruation, and recombinant human menopausal gonadotropins (150&#x02013;300 IU/day, Gonapure<sup>&#x000ae;</sup>; ASKA Pharmaceutical Co., Ltd.) or human menopausal gonadotropins (150&#x02013;300 IU/day, HMG Ferring<sup>&#x000ae;</sup>; Ferring Pharmaceuticals or HMG Teizo<sup>&#x000ae;</sup>; ASKA Pharmaceutical Co., Ltd.) were also administered while monitoring ovarian follicles. FF of mature follicles (diameter &#x0003e;18 mm) was aspirated by the administration of gonadotropin-releasing hormone (GnRH)-agonist (Suprecur<sup>&#x000ae;</sup>; Sanofi) at 36 hours before oocyte retrieval. GnRH-agonist (Suprecur<sup>&#x000ae;</sup>) was administered as nasal drops (one drop per nostril). Follicle aspirates that were not clear or were contaminated with blood were excluded. All samples were immediately centrifuged at 400 &#x000d7; <italic>g</italic> for 10 minutes, and the supernatant was stored frozen at &#x02212;70&#x000b0;C until assay. Collection of blood samples was performed by 48 hours before oocyte retrieval. Oocytes were cultured in Petri dishes in IVF20<sup>&#x000ae;</sup> (Vitrolife) at 37&#x000b0;C in a humidified 5% CO<sub>2</sub>/95% air environment. All patients provided written informed consent to participate in this study prior to enrollment. The research was approved by the ethics committee of Fujino Ladies Clinic, and conducted in accordance with the principles of the Declaration of Helsinki.</p><p>Determination of biopterin and neopterin concentrations was performed using high-performance liquid chromatography with fluorimetric detection.<xref rid="b11-jcm-6-2015-029" ref-type="bibr">11</xref>,<xref rid="b12-jcm-6-2015-029" ref-type="bibr">12</xref> In brief, 10 &#x003bc;L of 30% w/v trichloroacetic acid solution was added to 100 &#x003bc;L of serum and FF, and this mixture was centrifuged. A 10-&#x003bc;L volume of the mixture was kept at room temperature for 60 minutes. Excess iodine in the solution was removed by adding 15 &#x003bc;L of 1% aqueous ascorbic acid. Biopterin and neopterin concentrations in the supernatant were then measured.</p><p>Serum and FF concentrations of VEGF were measured using enzyme-linked immunosorbent assay (ELISA; Quantikine Human VEGF Immunoassay; R&#x00026;D Systems). This VEGF immunoassay is a solid-phase ELISA designed to measure the levels of VEGF-165 and contains Sf21-expressed, recombinant human VEGF-165 and antibodies raised against the recombinant protein. VEGF-121 and VEGF-165 are diffusible proteins secreted into the medium.<xref rid="b13-jcm-6-2015-029" ref-type="bibr">13</xref></p><p>M-CSF levels in serum and FF were measured using solid-phase ELISA (Quantikine M-CSF Immunoassay; R&#x00026;D Systems). This assay uses the quantitative sandwich enzyme immunoassay technique.</p><p>E2 and LH concentrations in serum were measured by time-resolved fluoroimmunoassay (DELFIA hormone assay; PerkinElmer) and radioimmunoassay (DPC Immulite; Siemens Japan), respectively.</p><sec sec-type="methods"><title>Statistical analysis</title><p>Statistical analysis was performed using SPSS version 20 software (IBM). Paired comparisons were analyzed using the unpaired Mann&#x02013;Whitney <italic>U</italic>-test. Differences were analyzed according to the <italic>c</italic><sup>2</sup> test. Values of <italic>P</italic> &#x0003c; 0.05 were considered statistically significant, and all data were expressed as median and range.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Patient characteristics are shown in <xref ref-type="table" rid="t1-jcm-6-2015-029">Table 1</xref>. Regarding the reasons for infertility, no difference was seen between the groups (<xref ref-type="table" rid="t2-jcm-6-2015-029">Table 2</xref>). Serum levels of E2 were significantly higher in Group 1 than in Group 2. The median number of oocytes retrieved was 5 (range, 4&#x02013;12) in Group 2. Our success rate for egg retrieval (more than one egg) was 91.8% (135/147 cases).</p><p>Serum and follicular concentrations in each group are shown in <xref ref-type="fig" rid="f1-jcm-6-2015-029">Figures 1</xref><xref ref-type="fig" rid="f2-jcm-6-2015-029"/><xref ref-type="fig" rid="f3-jcm-6-2015-029"/><xref ref-type="fig" rid="f4-jcm-6-2015-029"/>&#x02013;<xref ref-type="fig" rid="f5-jcm-6-2015-029">5</xref>. Biopterin levels from both serum and FF were significantly higher in Group 2 than in Group 1 (<italic>P</italic> = 0.002 in serum; <italic>P</italic> = 0.035 in FF). Conversely, neopterin and VEGF levels from both serum and FF and M-CSF levels from serum were significantly higher in Group 1 than in Group 2 (neopterin: <italic>P</italic> &#x0003c; 0.001 in serum and <italic>P</italic> = 0.005 in follicle; VEGF: <italic>P</italic> = 0.005 in serum and <italic>P</italic> = 0.035 in follicle; M-CSF: <italic>P</italic> = 0.007).</p><p>Neopterin/biopterin ratio in serum and FF was significantly higher in Group 1 than in Group 2 (<italic>P</italic> &#x0003c; 0.001 in serum; <italic>P</italic> = 0.005 in FF).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>This study measured concentrations of neopterin, biopterin, VEGF, and M-CSF in the serum and FF of infertile patients who underwent ovarian stimulation and oocyte retrieval. Our results first confirmed the existence of biopterin and neopterin in FF and revealed significant differences in concentrations between poor and good responders.</p><p>Biopterin, as a product of BH<sub>4</sub> metabolism, was significantly increased in both serum and FF of Group 2, and FF biopterin concentrations were similar to serum levels. BH<sub>4</sub> is a key cofactor in NOS, and NO has been shown to play crucial roles in follicular growth and angiogenesis, in addition to oocyte competence.<xref rid="b14-jcm-6-2015-029" ref-type="bibr">14</xref> Moreover, Bevers et al reported that BH<sub>4</sub> plays a determining role in the redox regulation of NOS-modulated endothelial responses.<xref rid="b15-jcm-6-2015-029" ref-type="bibr">15</xref> BH<sub>4</sub> has also been shown to decrease oxidant stress and increase levels of NO, which acts to restore blood flow after ischemia in rats.<xref rid="b16-jcm-6-2015-029" ref-type="bibr">16</xref> In this sense, our finding of a significant increase in BH<sub>4</sub> concentrations among good responders might be one explanation for follicular maturation.</p><p>Significantly increased neopterin levels were observed in both the serum and the FF of poor responders. In the synthetic pathway of BH<sub>4</sub>, the mechanism underlying increased neopterin levels together with decreased biopterin is thought to involve decreased activity of cofactors such as PTPS. However, PTPS activity was not investigated in the present study, and FF could potentially lack PTPS activity because of the lack of red blood cells.<xref rid="b17-jcm-6-2015-029" ref-type="bibr">17</xref> From another perspective, activated macrophages produce neopterin as a by-product of the guanosine triphosphate pathway, and elevated serum neopterin levels have been reported as an important biomarker of coronary and carotid atherosclerosis. Taken together with increased M-CSF levels in both serum and FF, abnormal cytokine responses in the serum of poor responders might influence neopterin levels in poor responders.<xref rid="b18-jcm-6-2015-029" ref-type="bibr">18</xref></p><p>Regarding ovarian angiogenesis, VEGF has been intensively investigated and a critical role has been identified in the regulation of follicular angiogenesis,<xref rid="b1-jcm-6-2015-029" ref-type="bibr">1</xref>,<xref rid="b19-jcm-6-2015-029" ref-type="bibr">19</xref> follicle&#x02013;luteal transition,<xref rid="b20-jcm-6-2015-029" ref-type="bibr">20</xref> control of luteal vascularization,<xref rid="b21-jcm-6-2015-029" ref-type="bibr">21</xref> blood flow, and luteal function.<xref rid="b22-jcm-6-2015-029" ref-type="bibr">22</xref> In clinical practice, poor responders to ovarian stimulation have been observed to show increased serum levels of VEGF,<xref rid="b4-jcm-6-2015-029" ref-type="bibr">4</xref> as indicated by our results. Grazul-Bilska et al<xref rid="b23-jcm-6-2015-029" ref-type="bibr">23</xref> reported that VEGF upregulates endothelial NOS expression in the ovine ovary, which would presumably mean that a higher demand for BH<sub>4</sub> would be present in the process of oocyte retrieval.</p><p>Limitations to the present study included the relatively small number of patients and the fact that groups were defined by the number of oocytes retrieved. Although we identified clear differences between the groups, production of BH<sub>4</sub> and neopterin within the follicle remains to be investigated, along with the synthetic pathways involved.</p><p>In conclusion, we have provided evidence of differences in serum and FF levels of biopterin and neopterin between poor responders and good responders at the time of oocyte retrieval. Decreased biopterin levels and increased neopterin levels in the serum of patients during ovarian stimulation appear to predict poor oocyte retrieval.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank all the patients and investigators involved in this study. This manuscript was kindly checked by a native English speaker, Matthew Morgan (FORTE, Tokyo, Japan).</p></ack><fn-group><fn id="fn1-jcm-6-2015-029"><p><bold>ACADEMIC EDITOR:</bold> Yasuo Ito, Editor in Chief</p></fn><fn id="fn2-jcm-6-2015-029"><p><bold>PEER REVIEW:</bold> Three peer reviewers contributed to the peer review report. Reviewers&#x02019; reports totaled 480 words, excluding any confidential comments to the academic editor.</p></fn><fn id="fn3-jcm-6-2015-029"><p><bold>FUNDING:</bold> None of the authors received funding for this study.</p></fn><fn id="fn4-jcm-6-2015-029"><p><bold>COMPETING INTERESTS:</bold> Authors disclose no potential conflicts of interest.</p></fn><fn id="fn5-jcm-6-2015-029"><p>Paper subject to independent expert blind peer review. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).</p></fn><fn id="fn6-jcm-6-2015-029"><p><bold>Author Contributions</bold></p><p>Conceived and designed the experiments: AH and DT. Analyzed the data: AH, DT, and HS. Wrote the first draft of the manuscript: AH, DT, TM, KO, YF, and NY. Contributed to the writing of the manuscript: AH, DT, and HS. Agree with manuscript results and conclusions: HS and MK. Jointly developed the structure and arguments for the paper: DT, HS, and MK. Made critical revisions and approved the final version: AH, DT, TM, HK, KO, YF, NY, HS, and MK. All authors reviewed and approved the final manuscript.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="b1-jcm-6-2015-029"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>HM</given-names></name><name><surname>Duncan</surname><given-names>WC</given-names></name></person-group><article-title>Regulation and manipulation of angiogenesis in the ovary and endometrium</article-title><source>Reprod Fertil Dev</source><year>2009</year><volume>21</volume><issue>3</issue><fpage>377</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">19261215</pub-id></element-citation></ref><ref id="b2-jcm-6-2015-029"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignarro</surname><given-names>LJ</given-names></name><name><surname>Byrns</surname><given-names>RE</given-names></name><name><surname>Buga</surname><given-names>GM</given-names></name><name><surname>Wood</surname><given-names>KS</given-names></name></person-group><article-title>Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical</article-title><source>Circ Res</source><year>1987</year><volume>61</volume><issue>6</issue><fpage>866</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">2890446</pub-id></element-citation></ref><ref id="b3-jcm-6-2015-029"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>JY</given-names></name><name><surname>Macchiarelli</surname><given-names>G</given-names></name><name><surname>Tsang</surname><given-names>BK</given-names></name><name><surname>Sato</surname><given-names>E</given-names></name></person-group><article-title>Capillary angiogenesis and degeneration in bovine ovarian antral follicles</article-title><source>Reproduction</source><year>2003</year><volume>125</volume><issue>2</issue><fpage>211</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">12578535</pub-id></element-citation></ref><ref id="b4-jcm-6-2015-029"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>CI</given-names></name><name><surname>Seifer</surname><given-names>DB</given-names></name><name><surname>Kennard</surname><given-names>EA</given-names></name><name><surname>Arbogast</surname><given-names>L</given-names></name><name><surname>Alak</surname><given-names>B</given-names></name><name><surname>Danforth</surname><given-names>DR</given-names></name></person-group><article-title>Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential</article-title><source>Fertil Steril</source><year>1998</year><volume>70</volume><issue>5</issue><fpage>836</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">9806563</pub-id></element-citation></ref><ref id="b5-jcm-6-2015-029"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barroso</surname><given-names>G</given-names></name><name><surname>Barrionuevo</surname><given-names>M</given-names></name><name><surname>Rao</surname><given-names>P</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor, nitric oxide, and leptin follicular fluid levels correlate negatively with embryo quality in IVF patients</article-title><source>Fertil Steril</source><year>1999</year><volume>72</volume><issue>6</issue><fpage>1024</fpage><lpage>1026</lpage><pub-id pub-id-type="pmid">10593375</pub-id></element-citation></ref><ref id="b6-jcm-6-2015-029"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moncada</surname><given-names>S</given-names></name><name><surname>Higgs</surname><given-names>A</given-names></name></person-group><article-title>The L-arginine-nitric oxide pathway</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><issue>27</issue><fpage>2002</fpage><lpage>2012</lpage><pub-id pub-id-type="pmid">7504210</pub-id></element-citation></ref><ref id="b7-jcm-6-2015-029"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppen</surname><given-names>A</given-names></name><name><surname>Swade</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>SA</given-names></name><name><surname>Armstrong</surname><given-names>RA</given-names></name><name><surname>Blair</surname><given-names>JA</given-names></name><name><surname>Leeming</surname><given-names>RJ</given-names></name></person-group><article-title>Depression and tetrahydrobiopterin: the folate connection</article-title><source>J Affect Disord</source><year>1989</year><volume>16</volume><issue>2&#x02013;3</issue><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">2522108</pub-id></element-citation></ref><ref id="b8-jcm-6-2015-029"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Th&#x000f6;ny</surname><given-names>B</given-names></name><name><surname>Auerbach</surname><given-names>G</given-names></name><name><surname>Blau</surname><given-names>N</given-names></name></person-group><article-title>Tetrahydrobiopterin biosynthesis, regeneration and functions</article-title><source>Biochem J</source><year>2000</year><volume>347</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">10727395</pub-id></element-citation></ref><ref id="b9-jcm-6-2015-029"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferraretti</surname><given-names>AP</given-names></name><name><surname>Gianaroli</surname><given-names>L</given-names></name><name><surname>Magli</surname><given-names>MC</given-names></name><name><surname>Devroey</surname><given-names>P</given-names></name></person-group><article-title>Mild ovarian stimulation with clomiphene citrate launch is a realistic option for in vitro fertilization</article-title><source>Fertil Steril</source><year>2015</year><volume>104</volume><issue>2</issue><fpage>333</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">26051093</pub-id></element-citation></ref><ref id="b10-jcm-6-2015-029"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauser</surname><given-names>BC</given-names></name><name><surname>Devroey</surname><given-names>P</given-names></name><name><surname>Yen</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks</article-title><source>Hum Reprod</source><year>1999</year><volume>14</volume><issue>11</issue><fpage>2681</fpage><lpage>2686</lpage><pub-id pub-id-type="pmid">10548600</pub-id></element-citation></ref><ref id="b11-jcm-6-2015-029"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukushima</surname><given-names>T</given-names></name><name><surname>Nixon</surname><given-names>JC</given-names></name></person-group><article-title>Analysis of reduced forms of biopterin in biological tissues and fluids</article-title><source>Anal Biochem</source><year>1980</year><volume>102</volume><issue>1</issue><fpage>176</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">7356152</pub-id></element-citation></ref><ref id="b12-jcm-6-2015-029"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niederwieser</surname><given-names>A</given-names></name><name><surname>Staudenmann</surname><given-names>W</given-names></name><name><surname>Wetzel</surname><given-names>E</given-names></name></person-group><article-title>High-performance liquid chromatography with column switching for the analysis of biogenic amine metabolites and pterins</article-title><source>J Chromatogr</source><year>1984</year><volume>290</volume><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">6736163</pub-id></element-citation></ref><ref id="b13-jcm-6-2015-029"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tischer</surname><given-names>E</given-names></name><name><surname>Mitchell</surname><given-names>R</given-names></name><name><surname>Hartman</surname><given-names>T</given-names></name><etal/></person-group><article-title>The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing</article-title><source>J Biol Chem</source><year>1991</year><volume>266</volume><issue>18</issue><fpage>11947</fpage><lpage>11954</lpage><pub-id pub-id-type="pmid">1711045</pub-id></element-citation></ref><ref id="b14-jcm-6-2015-029"><label>14</label><element-citation publication-type="journal" id="b14-jcm-6-2015-029-gen-2"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>A</given-names></name><name><surname>Black</surname><given-names>SM</given-names></name><name><surname>Catravas</surname><given-names>JD</given-names></name></person-group><article-title>Endothelial nitric oxide (NO) and its pathophysiologic regulation</article-title><source>Vascul Pharmacol</source><year>2008</year><volume>49</volume><issue>4&#x02013;6</issue><fpage>134</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.vph.200806.008</pub-id><comment>Epub 2008 Jul 20. Review</comment><pub-id pub-id-type="pmid">18692595</pub-id></element-citation><element-citation publication-type="journal" id="b14-jcm-6-2015-029-gen-3"><article-title>Erratum</article-title><source>Vascul Pharmacol</source><year>2009</year><volume>50</volume><issue>5&#x02013;6</issue><fpage>208</fpage></element-citation></ref><ref id="b15-jcm-6-2015-029"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bevers</surname><given-names>LM</given-names></name><name><surname>Braam</surname><given-names>B</given-names></name><name><surname>Post</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase</article-title><source>Hypertension</source><year>2006</year><volume>47</volume><issue>1</issue><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">16344367</pub-id></element-citation></ref><ref id="b16-jcm-6-2015-029"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Tie</surname><given-names>G</given-names></name><name><surname>Messina</surname><given-names>LM</given-names></name></person-group><article-title>Tetrahydrobiopterin, L-arginine and vitamin C act synergistically to decrease oxidant stress and increase nitric oxide that increases blood flow recovery after hindlimb ischemia in the rat</article-title><source>Mol Med</source><year>2012</year><volume>18</volume><fpage>1221</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">23212846</pub-id></element-citation></ref><ref id="b17-jcm-6-2015-029"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shintaku</surname><given-names>H</given-names></name><name><surname>Niederwieser</surname><given-names>A</given-names></name><name><surname>Leimbacher</surname><given-names>W</given-names></name><name><surname>Curtius</surname><given-names>HC</given-names></name></person-group><article-title>Tetrahydrobiopterin deficiency: assay for 6-pyruvoyl-tetrahydropterin synthase activity in erythrocytes, and detection of patients and heterozygous carriers</article-title><source>Eur J Pediatr</source><year>1988</year><volume>147</volume><issue>1</issue><fpage>15</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">3276524</pub-id></element-citation></ref><ref id="b18-jcm-6-2015-029"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gieseg</surname><given-names>SP</given-names></name><name><surname>Crone</surname><given-names>EM</given-names></name><name><surname>Flavall</surname><given-names>EA</given-names></name><name><surname>Amit</surname><given-names>Z</given-names></name></person-group><article-title>Potential to inhibit growth of atherosclerotic plaque development through modulation of macrophage neopterin/7,8-dihydroneopterin synthesis</article-title><source>Br J Pharmacol</source><year>2008</year><volume>153</volume><issue>4</issue><fpage>627</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">17700723</pub-id></element-citation></ref><ref id="b19-jcm-6-2015-029"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>RS</given-names></name><name><surname>Woad</surname><given-names>KJ</given-names></name><name><surname>Hammond</surname><given-names>AJ</given-names></name><name><surname>Laird</surname><given-names>M</given-names></name><name><surname>Hunter</surname><given-names>MG</given-names></name><name><surname>Mann</surname><given-names>GE</given-names></name></person-group><article-title>Angiogenesis and vascular function in the ovary</article-title><source>Reproduction</source><year>2009</year><volume>138</volume><issue>6</issue><fpage>869</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">19786399</pub-id></element-citation></ref><ref id="b20-jcm-6-2015-029"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>LP</given-names></name><name><surname>Redmer</surname><given-names>DA</given-names></name></person-group><article-title>Growth and development of the corpus luteum</article-title><source>J Reprod Fertil Suppl</source><year>1999</year><volume>54</volume><fpage>181</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">10692854</pub-id></element-citation></ref><ref id="b21-jcm-6-2015-029"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berisha</surname><given-names>B</given-names></name><name><surname>Steffl</surname><given-names>M</given-names></name><name><surname>Amselgruber</surname><given-names>W</given-names></name><name><surname>Schams</surname><given-names>D</given-names></name></person-group><article-title>Changes in fibroblast growth factor 2 and its receptors in bovine follicles before and after GnRH application and after ovulation</article-title><source>Reproduction</source><year>2006</year><volume>131</volume><issue>2</issue><fpage>319</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">16452725</pub-id></element-citation></ref><ref id="b22-jcm-6-2015-029"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>RS</given-names></name><name><surname>Nicklin</surname><given-names>LT</given-names></name><name><surname>Hammond</surname><given-names>AJ</given-names></name><name><surname>Schams</surname><given-names>D</given-names></name><name><surname>Hunter</surname><given-names>MG</given-names></name><name><surname>Mann</surname><given-names>GE</given-names></name></person-group><article-title>Fibroblast growth factor 2 is more dynamic than vascular endothelial growth factor A during the follicle-luteal transition in the cow</article-title><source>Biol Reprod</source><year>2007</year><volume>77</volume><issue>1</issue><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">17360962</pub-id></element-citation></ref><ref id="b23-jcm-6-2015-029"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grazul-Bilska</surname><given-names>AT</given-names></name><name><surname>Navanukraw</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>ML</given-names></name><name><surname>Arnold</surname><given-names>DA</given-names></name><name><surname>Reynolds</surname><given-names>LP</given-names></name><name><surname>Redmer</surname><given-names>DA</given-names></name></person-group><article-title>Expression of endothelial nitric oxide synthase in the ovine ovary throughout the estrous cycle</article-title><source>Reproduction</source><year>2006</year><volume>132</volume><issue>4</issue><fpage>579</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">17008469</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-jcm-6-2015-029" position="float"><label>Figure 1</label><caption><p>Serum (<bold>A</bold>) and FF (<bold>B</bold>) biopterin levels in each group. Median (black bars), interquartile range (IQR; boxes), and values within 1.5 IQR (whiskers) are shown.</p></caption><graphic xlink:href="jcm-6-2015-029f1"/></fig><fig id="f2-jcm-6-2015-029" position="float"><label>Figure 2</label><caption><p>Serum (<bold>A</bold>) and FF (<bold>B</bold>) neopterin levels in each group. Median (black bars), IQR (boxes), values within 1.5 IQR (whiskers), and values exceeding 3.0 IQR (asterisks) are shown.</p></caption><graphic xlink:href="jcm-6-2015-029f2"/></fig><fig id="f3-jcm-6-2015-029" position="float"><label>Figure 3</label><caption><p>Serum (<bold>A</bold>) and FF (<bold>B</bold>) neopterin/biopterin ratio in each group. Median (black bars), IQR (boxes), values within 1.5 IQR (whiskers), and values exceeding 1.5 IQR (circles) and 3.0 IQR (asterisks) are shown.</p></caption><graphic xlink:href="jcm-6-2015-029f3"/></fig><fig id="f4-jcm-6-2015-029" position="float"><label>Figure 4</label><caption><p>Serum (<bold>A</bold>) and FF (<bold>B</bold>) VEGF levels in each group. Median (black bars), IQR (boxes), values within 1.5 IQR (whiskers), and values exceeding 1.5 IQR (circles) and 3.0 IQR (asterisks) are shown.</p></caption><graphic xlink:href="jcm-6-2015-029f4"/></fig><fig id="f5-jcm-6-2015-029" position="float"><label>Figure 5</label><caption><p>Serum (<bold>A</bold>) and FF (<bold>B</bold>) M-CSF levels in each group. Median (black bars), IQR (boxes), values within 1.5 IQR (whiskers), and values exceeding 1.5 IQR (circles) and 3.0 IQR (asterisks) are shown.</p></caption><graphic xlink:href="jcm-6-2015-029f5"/></fig><table-wrap id="t1-jcm-6-2015-029" position="float"><label>Table 1</label><caption><p>Patient characteristics in this study (median, range).</p></caption><table frame="box" rules="rows"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">GROUP 1 (n = 12)</th><th valign="top" align="left" rowspan="1" colspan="1">GROUP 2 (n = 13)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">40 (30&#x02013;44)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (33&#x02013;43)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">18.7 (17.7&#x02013;23.3)</td><td valign="top" align="left" rowspan="1" colspan="1">18.6 (17.7&#x02013;25.6)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of infertility (months)</td><td valign="top" align="left" rowspan="1" colspan="1">48 (36&#x02013;204)</td><td valign="top" align="left" rowspan="1" colspan="1">72 (30&#x02013;132)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Estradiol (pg/ml)</td><td valign="top" align="left" rowspan="1" colspan="1">450 (193&#x02013;660)</td><td valign="top" align="left" rowspan="1" colspan="1">915 (463&#x02013;3000)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LH (pg/ml)</td><td valign="top" align="left" rowspan="1" colspan="1">7.9 (3.1&#x02013;19.9)</td><td valign="top" align="left" rowspan="1" colspan="1">6.6 (4.4&#x02013;13.2)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total gonadotropin dose (IU)</td><td valign="top" align="left" rowspan="1" colspan="1">150 (50&#x02013;450)</td><td valign="top" align="left" rowspan="1" colspan="1">150 (0&#x02013;450)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-jcm-6-2015-029"><p><bold>Notes:</bold> Serum estradiol and LH were measured 48 hours before oocyte retrieval. Group 1: unsuccessful oocyte retrieval. Group 2: retrieval of more than four oocytes.</p></fn><fn id="tfn2-jcm-6-2015-029"><p><bold>Abbreviation:</bold> NS, not significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-jcm-6-2015-029" position="float"><label>Table 2</label><caption><p>Reasons for infertility in both groups.</p></caption><table frame="box" rules="rows"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">GROUP 1 (n = 12)</th><th valign="top" align="left" rowspan="1" colspan="1">GROUP 2 (n = 13)</th><th valign="top" align="left" rowspan="1" colspan="1">TOTAL</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Tubal occlusion</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Endometriosis</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male factor</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Unexplained infertility</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">18</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-jcm-6-2015-029"><p><bold>Notes:</bold> Group 1: unsuccessful oocyte retrieval. Group 2: retrieval of more than four oocytes.</p></fn></table-wrap-foot></table-wrap></floats-group></article>